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Oligoribonucleases are conserved enzymes that
degrade short RNA molecules of up to 5 nt in length
and are assumed to constitute the final stage of
RNA turnover. Here we demonstrate that REXO2 is a
specialized dinucleotide-degrading enzyme that
shows no preference between RNA and DNA dinucle-
otide substrates. A heart- and skeletal-muscle-spe-
cific knockout mouse displays elevated dinucleotide
levels and alterations in gene expression patterns
indicative of aberrant dinucleotide-primed transcrip-
tion initiation.We find that dinucleotides act as potent
stimulators of mitochondrial transcription initiation
in vitro. Our data demonstrate that increased levels
of dinucleotides can be used to initiate transcription,
leading to an increase in transcription levels from
both mitochondrial promoters and other, nonspecific
sequence elements in mitochondrial DNA. Efficient
RNA turnover by REXO2 is thus required to maintain
promoter specificity and proper regulation of tran-
scription in mammalian mitochondria.
INTRODUCTION
The mammalian mitochondrial genome encodes 13 essential
protein components of themitochondrial oxidative phosphoryla-
tion system, as well as the full complement of tRNAs and rRNAs
required for the synthesis of these proteins within mitochondria.Molecular Cell 76, 1–13, D
This is an open access article under the CC BY-NThe life cycle of a mitochondrial RNA (mtRNA) molecule begins
with transcription initiation from one of two promoters, the
light-strand promoter (LSP) or the heavy-strand promoter
(HSP) (Gustafsson et al., 2016). Transcription initiation minimally
requires three proteins comprising a bacteriophage T7-like
mtRNA polymerase (POLRMT) together with mitochondrial tran-
scription factor A (TFAM) and transcription factor B2 (TFB2M)
(Falkenberg et al., 2002; Shi et al., 2012). A stepwise model for
mitochondrial transcription initiation has been elucidated from
biochemical and structural studies in recent years. First, TFAM
binds to the promoter region, imposing a sharp U-turn in the
DNA and recruiting POLRMT, which becomes positioned at
the transcription start site (TSS) (Gaspari et al., 2004; Morozov
et al., 2014). TFB2M then binds to this complex and facilitates
melting of the promoter DNA (Hillen et al., 2017; Morozov
et al., 2015; Posse and Gustafsson, 2017; Sologub et al.,
2009), allowing POLRMT to initiate RNA synthesis.
Transcription in mitochondria is polycistronic, with mRNAs
and rRNAs interspersed (‘‘punctuated’’) with tRNAs (Ojala
et al., 1981). Once these tRNAs have folded into their canonical
cloverleaf structures in the precursor RNAs, they are recognized
and cleaved at their 50 and 30 ends by RNase P and ELAC2,
respectively (Brzezniak et al., 2011; Holzmann et al., 2008; San-
chez et al., 2011), which serve to excise individual transcripts.
The degradation of mtRNAs has long been poorly understood
but has seen several recent advances. The most well-character-
ized degradation machinery in the humanmitochondrial matrix is
a complex of the phosphorylytic exoribonuclease PNPase with
the helicase SUV3, collectively termed the RNA degradosome
(Borowski et al., 2013; Szczesny et al., 2010). PNPase proces-
sively releases mononucleoside diphosphates as reaction prod-
ucts but is unable to degrade short RNA molecules of less thanecember 5, 2019 ª 2019 The Authors. Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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PNPase causes the accumulation of antisense RNAs (Pietras
et al., 2018) as well as double-stranded RNAs (Dhir et al.,
2018), implicating a role for PNPase in the removal of these mol-
ecules, and it remains unclear which other RNases also
contribute to RNA turnover.
In E. coli, the final stage of RNA degradation is the hydrolysis of
short RNA fragments of 2–5 nt in length, termed nanoRNAs
(Mechold et al., 2007). This process requires the conserved
and essential oligoribonuclease Orn (Ghosh and Deutscher,
1999; Niyogi and Datta, 1975). Orn is a 30-50 exonuclease of
the DEDDh family that releases mononucleotides as reaction
products (Datta and Niyogi, 1975) and was recently found to
show a strong preference for dinucleotide substrates (Kim
et al., 2019). The loss of Orn results in large-scale alterations in
gene expression that have been attributed to the ability of nano-
RNAs to mediate transcription priming (Druzhinin et al., 2015;
Goldman et al., 2011; Vvedenskaya et al., 2012).
The human homolog of Orn is called REXO2 and is an active
ribonuclease (Mechold et al., 2006; Nguyen et al., 2000) that lo-
calizes to the mitochondrial matrix, the intermembrane space,
and the cytosol (Bruni et al., 2013). Depletion of REXO2 in human
cells causes severe effects on mitochondrial DNA copy number,
mitochondrial transcript levels, and mitochondrial translation
(Bruni et al., 2013), but the molecular basis for these wide-
ranging effects on mitochondrial gene expression are unclear.
In this work, we reassess the role of REXO2 in mitochondria.
We find that REXO2 is a sugar-independent dinucleotide-de-
grading enzyme, as supported by in vitro biochemistry and crys-
tal structures of the apo and substrate-bound enzyme forms. We
find that REXO2 is an essential gene inmice and that a heart- and
skeletal-muscle-specific conditional knockout model exhibits
changes in both promoter-dependent and promoter-indepen-
dent transcription initiation indicating dinucleotide-mediated
priming of mitochondrial transcription from both canonical and
non-canonical sites.
Therefore we conclude that the activity of REXO2 is essential
for both RNA turnover and the maintenance of promoter speci-
ficity in mammalian mitochondria.
RESULTS
REXO2 Is an RNA and DNA Dinucleotidase
REXO2 degrades oligonucleotides of5 nt in length, with a pref-
erence for RNA substrates (Chu et al., 2019; Nguyen et al., 2000).
We expressed and purified full-length human REXO2 from E. coli
(Figure S1A) and assessed the activity of the recombinant pro-
tein upon nanoRNA substrates in vitro. REXO2 exhibited a strong
preference for dinucleotides relative to 3-, 4-, or 5-mer sub-
strates, with little sequence specificity (Figures 1A and 1B).
RNA 3-, 4-, or 5-mers could be fully degraded only at significantly
higher enzyme concentrations (Figures S1B and S1D). Surpris-
ingly, when the activity of recombinant REXO2 was assessed
upon DNA oligonucleotides of equivalent sequences, a compa-
rable activity was observed as the one obtained with RNA dinu-
cleotides (Figures 1C and 1D). However, no activity was
observed upon longer DNA oligos of 3–5 nt in length at these
enzyme concentrations (Figures 1C and 1D) or even at higher2 Molecular Cell 76, 1–13, December 5, 2019concentrations (Figures S1C and S1E), demonstrating that this
sugar-nonspecific activity of REXO2 is restricted to dinucleotide
substrates.
Structural Basis for REXO2 Substrate Specificity
To gain molecular insight into the mechanism and specificity of
nucleotide degradation by REXO2, we crystallized the human
protein comprising residues 39–216, which retains catalytic ac-
tivity (Figures S1F–S1I), and determined its structure to 2.0 A˚ res-
olution (Table 1). As previously reported (Chu et al., 2019; Kim
et al., 2019), the protein crystallizes as a dimer and has an
RNase-H-like fold that is composed of five central b strands sur-
rounded by nine a helices on opposite sides (Figures 2A and
S2C). Each monomer harbors an active site formed by the
conserved acidic DEDD residues D47, E49, D147, and D199
that are positioned for nucleotide binding (Figure 2A), and muta-
tion of any one of the conserved DEDD residues to alanine
severely impaired the catalytic activity of the enzyme (Figures
2B–2D), consistent with their key role in catalysis.
In order to understand the structural basis of the observed
substrate specificity, we determined the structure of REXO2
complexed with either an RNA dinucleotide (pApA) or DNA dinu-
cleotide (dAdA) in an arrested pre-catalytic state bymutating one
of the DEDDh residues, D199A (Figures 2E–2G, S3B, and S3C;
Table 1). The binding of dinucleotides produced only a few sig-
nificant changes in the protein structure, mainly confined to a
‘‘trigger loop’’ between a9 and a10 of monomer A. This contains
H194, which makes a 180 shift toward the active site to bind
Zn2+ and the phosphate oxygen OP1 of the 30 nucleotide. This
structural arrangement is in stark contrast to the apoprotein, in
which the DEDDh residue H194 faces away from the active site
(Figures 2A and S3A). On the 50 end of the dinucleotide, S143
and S170 of monomer A and R165 of monomer B form hydrogen
bonds with OP1 of the nucleotide monophosphate, creating a
physical boundary of the narrow active site that impedes binding
of longer substrates (Figure 2G). Indeed, a structural comparison
to other DEDD exonucleases (Figures S3D–S3F; Table S1)
confirmed that a steric clash would be imposed starting from
the third nucleotide, with additional clashes from nucleotide
four and beyond, providing the structural basis for the strong
preference of REXO2 for dinucleotide substrates.
The REXO2 dimer forms an extensive binding interface that
corresponds to 16% of the surface area of each monomer (Fig-
ures 3A and S3G). To validate the functional importance of
dimerization, we created amino acid substitutions designed to
break this interface (Figures 3A, 3B, and S3H–S3K) and found
that mutations that disrupt dimerization (Figure 3C) lead to a
loss of enzymatic activity (Figure 3D).
REXO2 Is Essential for Embryonic Development
To investigate the in vivo importance for REXO2’s ability to
degrade dinucleotides, we generated a Rexo2 conditional
knockout allele (Rexo2+/loxP) using the Cre-loxP system. Het-
erozygous knockout mice (Rexo2+/) were obtained by
breeding Rexo2+/loxP mice with transgenic mice expressing
Cre recombinase (+/b-actin-cre) (Figure S4A). Intercrossing
of Rexo2+/ mice produced no viable homozygous knockout
(Rexo2/) mice (analyzed offspring, n = 119; Rexo2+/+,
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Figure 1. Human REXO2 Is a Dinucleotidase
(A) Activity of wild-type REXO2 upon RNA substrates of different lengths. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the indicated
amount of REXO2 at 37C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.
(B) Quantification of RNA degradation by REXO2 from (A).
(C) Activity of wild-type REXO2 upon DNA substrates of different lengths. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the indicated
amount of REXO2 at 37C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.
(D) Quantification of DNA degradation by REXO2 from (C).
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lecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.09.010n = 48; Rexo2+/, n = 71; and Rexo2/, n = 0), indicating that
loss ofRexo2 results in embryonic lethality. Next, we performed
an intercross of Rexo2+/ mice and analyzed embryos at em-
bryonic day 8.5 (E8.5; analyzed embryos, n = 13). Embryos
with the Rexo2+/+ (n = 3) or Rexo2+/ (n = 8) genotype were
well developed with normal appearance (Figure 4A), while em-
bryos with the Rexo2/ genotype (n = 2) were small and lacked
heart structure (Figure 4B). Thus, Rexo2 is essential for embry-
onic development, and loss of REXO2 causes embryonic
lethality before E8.5.
We next disrupted Rexo2 in heart and skeletal muscle by
breeding Rexo2+/loxP mice with transgenic mice expressingCre recombinase from the muscle creatinine kinase
promoter (Ckmm-cre). The conditional knockout Rexo2 mice
(Rexo2loxP/loxP, +/Ckmm-cre), hereafter denoted L/L, cre,
were born at expected Mendelian ratios. Loss of REXO2 in
heart was verified using western blotting (Figure 4C) and
qPCR analyses (Figure S4B). The loss of REXO2 in heart and
skeletal muscle did not lead to any obvious phenotype, and
all mice were viable and healthy at the age of 52 weeks. No dif-
ferences were observed between control and Rexo2 knockout
mice in body weight (Figure S4C), heart weight (Figure S4D), or
mtDNA copy number (Figure 4D). We used northern blotting to
analyze the effects of REXO2 loss on steady-state levels ofMolecular Cell 76, 1–13, December 5, 2019 3
Table 1. Data Collection and Refinement Statistics
REXO2
REXO2-
D199A-pApA
REXO2-
D199A-dAdA
Data Collection
Wavelength (A˚) 0.9184 0.9762 1.2824
Space group C2221 C2221 C2221
Cell dimensions
a, b, c (A˚) 36.2, 128.5,
170.2
35.6, 125.8,
167.9
35.8, 126.9,
168.2
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (A˚) 42.6–2.0
(2.12-2.00)
42.0–2.0
(2.04-1.97)
42.1-2.25
(2.38-2.25)
Rmeas (%) 10.8 (93.5) 8.0 (165.8) 7.7 (150.4)
CC1/2 99.7 (56.4) 99.9 (69.9) 99.9 (53.6)
I /s(I) 8.47 (1.26) 13.4 (1.1) 14.2 (1.2)
Completeness (%) 98.8 (97.8) 100.0 (100.0) 99.7 (98.6)
Refinement
Resolution (A˚) 22.7-2.00
(2.01-2.00)
41.98-1.97
(1.98-1.97)
21.8-2.25
(2.33-2.25)
No. reflections 27274 27319 18796
Rwork/Rfree 0.1978/
0.2322
0.2029/
0.2512
0.2121/
0.2480
No. atoms
Protein 2663 2675 2675
Nucleic acid 44 42
Water 247 197 83
B-factors
Protein 48.97 58.33 73.27
Nucleic acid 57.00 71.63
Water 51.49 62.60 69.90
RMSDs
Bond lengths (A˚) 0.010 0.010 0.010
Bond angles () 1.59 1.58 1.58
Ramachandran
plot favored/
allowed (%)a
99.37/0.63 99.06/0.94 99.38/0.62
Clashscorea 1.13 1.85 1.11
Molprobity scorea 0.82 0.95 0.82
Statistics for the highest-resolution shell are shown in parentheses.aAc-
cording to the definition used in Molprobity (Lovell et al., 2003).
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lecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.09.010mtRNAs and found that there were no significant differences in
the levels of mitochondrial rRNAs (mt-rRNAs), mitochondrial
mRNAs (mt-mRNAs), and mitochondrial tRNAs (mt-tRNAs) be-
tween Rexo2 knockout mice and controls (Figures 4E, 4F, S4E,
and S4F). To determine whether mitochondrial dinucleotides
are in vivo substrates of REXO2, we measured the abundance
of the pApA RNA dinucleotide using liquid-chromatography-
tandem mass spectrometry (LC-MS/MS). A marked increase
in the level of RNA pApA was observed in both whole heart
tissue (Figure 4G) and isolated mitochondria (Figure 4H) in the
absence of REXO2, suggesting that this is a substrate of
mitochondrial REXO2 in vivo.4 Molecular Cell 76, 1–13, December 5, 2019Accumulation of Dinucleotides Results in Promoter-
Independent Transcription Initiation
We used parallel analyses of RNA ends (PARE) to determine the
distribution of 5ʹ ends across the entire mitochondrial transcrip-
tome and reveal additional mitochondrial gene expression
changes in the absence of REXO2. This method captures
20-nt-long tags from the 5ʹ ends of 5ʹ-monophosphorylated
RNAs (Rackham et al., 2016), with the normalized read count
at each 5ʹ terminal position appearing as a peak enabling the
identification of 5ʹ sites from canonical, de novo, or degraded
transcripts. We identified numerous non-canonical peaks that
are enriched in the absence of REXO2 (Figure 5A, shown in
red). To assess whether these changes may be attributed to
alterations of ribonucleoside triphosphate (NTP) levels in the
absence of REXO2, we measured nucleotide concentrations
from either whole heart tissue or isolated mitochondria of wild-
type and Rexo2 knockout mice (Figures S5A and S5B), which
did not reveal any significant differences. However, by analyzing
the frequency of different dinucleotide sequences at the 5ʹ ends
of captured sequence tags, we found that in Rexo2 knockout
mice, there was an enrichment of AA, AC, and AT dinucleotides,
while all other 5ʹ dinucleotides were depleted (Figure 5B). As ATP
is used as the initiating nucleotide at both promoters in vivo by
the mtRNA polymerase, we reasoned that the accumulation of
dinucleotides (Figures 4G–4H) upon loss of REXO2 may prime
low levels of transcription at non-canonical sites.
To validate this finding, we used a reconstituted human mito-
chondrial in vitro transcription system consisting of POLRMT
and the two essential transcription factors, TFAM and TFB2M
(Falkenberg et al., 2002). Transcription initiation by this com-
plex usually requires one of the two mtDNA promoters, LSP
or HSP. Accordingly, no transcription initiation is observed us-
ing a plasmid template lacking a promoter sequence (Figure 5C,
lane 3). However, upon the addition of oligonucleotide(A) nano-
RNAs to this reaction, we observed robust transcription initia-
tion in the absence of a recognizable promoter (Figure 5C, lanes
4–7). Transcription initiation without a promoter was only
observed using RNA primers (Figure 5C, compare lanes 4–7
with lanes 8–11) and only with closed circular templates, not
with linear templates (Figure 5D). This indicates that negative
supercoiling of circular DNA molecules is required for nano-
RNAs to access the template in order to prime transcription.
The ability of nanoRNAs to prime transcription remained
evident at low concentrations relative to that of the normal initi-
ating nucleotide ATP (Figures S5C and S5D), indicating that
nanoRNAs are potent primers of promoter-independent
mitochondrial transcription. Furthermore, by using nanoRNAs
of different sequences, we found that different nanoRNA
sequences are capable of priming promoter nonspecific tran-
scription providing that the 3ʹ end contains a pair of adenine
residues (Figure S5E, lanes 10–14), highlighting their potential
to exert broad effects upon transcription.
nanoRNAs Stimulate Promoter-Dependent
Transcription Initiation
Next, we investigated the effects of the loss of REXO2 upon pro-
moter-dependent transcription initiation from the two mtDNA
promoters, LSP and HSP. The rate of transcription initiation
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Figure 2. Structural Basis of REXO2 Sub-
strate Specificity
(A) Front view of the overall structure of REXO2.
Monomer A (gray) and monomer B (blue) are
shown in cartoon representation with the DEDDh
residues of monomer A shown as sticks. Stars
indicate the active sites of monomer A and
monomer B. Monomer B lacked clear density for
regions encompassing helices a2–4 (residues 84–
113) and a short loop corresponding to residues
189–192 and were therefore not built in the model.
(B) Activity of truncated REXO2 variants (amino
acids 39–216) upon RNA or DNA AA dinucleotide
substrates. Monophosphorylated radiolabeled
substrate (10 fmol) was incubated with the indi-
cated amounts of REXO2 at 37C for 30 min,
separated by 18% urea-PAGE, and imaged by
autoradiography.
(C) Quantification of RNA degradation by REXO2
variants from (B).
(D) Quantification of DNA degradation by REXO2
variants as in (B).
(E) Surface representation of REXO2 with the RNA
pApA dinucleotide (yellow) shown as sticks. The
molecular surface is colored by the local electro-
static potential (blue, +5 kT; red, 5 kT).
(F) Enlargement of REXO2 active site with bound
RNA pApA dinucleotide as in (E).
(G) The REXO2 active site. Residues interacting
with the RNA pApA dinucleotide (orange) are
shown as sticks and the polar bonds as yellow
dashes. Zn2+ and Mg2+ are shown as pink and
green spheres, respectively. Water molecules are
shown as gray spheres.
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lecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.09.010from both the HSP and LSP was increased in the Rexo2
knockout mice (Figures 6A and 6B), albeit only slightly, consis-
tent with the finding that loss of REXO2 in the heart does not
cause significant pathology. It is likely that highly proliferative tis-
sues and cells are more affected by the loss of REXO2, as the
clearance of dinucleotides would be more important at
increased proliferation rates. Interestingly, PARE data showed
that the most enriched 5ʹ end in the LSP region is positioned at
the transcription initiation site and would give rise to transcriptsMowith 5ʹ-AG dinucleotides despite these
being depleted overall in the knockout
mice (Figure 5B). These findings suggest
that transcription primedwith AG dinucle-
otides is more efficient at the promoter
than elsewhere in the genome.
To test the capacity of nanoRNAs to
prime promoter-dependent transcription
initiation, we used a reconstituted human
in vitro transcription systemwith templates
containing either the human LSP or HSP
sequence. nanoRNAs that anneal to the
promoter at the TSS were found to
potently stimulate transcription initiation
from both the LSP and HSP (Figures 6C
and 6D). Similar to the observation ofnanoRNA-primed transcription in the absence of a promoter (Fig-
ure S5E), the promoter-dependent effectwas only observed using
oligonucleotides containing AA at the 30 end (Figures 6C and 6D).
However, in contrast to results obtained with promoter-less tem-
plates, nanoRNAs are capable of priming promoter-dependent
transcription using both linear templates and supercoiled tem-
plates (Figures 6C and 6D, compare lanes 3–8 with lanes 9–14).
Although supercoiling was dispensable, nanoRNA-primed tran-
scription remained absolutely dependent on the presence oflecular Cell 76, 1–13, December 5, 2019 5
Figure 3. REXO2 Is an Obligate Homodimer
(A) Top and front views of the surface of REXO2 with monomer A (blue) and monomer B (pink), where the interface interacting residues are highlighted in darker
colors. K216 is highlighted in green, and R178, W179, and L175 are highlighted in yellow.
(B)TheR178-W179bindingpocket isshown incartoonrepresentationwithR178,W179,and their interacting residuesshownasstickswith thesamecolorcodeas in (A).
(C) Gel filtration profiles of the REXO2 dimer mutants.
(D) Activity of REXO2 dimerization mutants upon RNA or DNA AA dinucleotides. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the
indicated amounts of REXO2 protein at 37C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.
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lecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.09.010TFB2M (Figures S6A and S6B, compare lanes 3–8 with lanes
9–14), which contributes critically to promoter melting (Hillen
et al., 2017; Morozov et al., 2015; Posse and Gustafsson, 2017;
Sologub et al., 2009). The stimulation of transcription initiation
by nanoRNAs was again observed at concentrations of nanoRNA6 Molecular Cell 76, 1–13, December 5, 2019much lower than that of ATP (Figures S6C and S6D) and was not
seen using DNA primers (Figures S6E and S6F), indicating that
nanoRNAs are used in preference to ATP to initiate transcription.
Interestingly, the RNA4-mer AAAAwas able to prime transcription
initiation from HSP despite not fully annealing to the promoter
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Figure 4. REXO2 Is Essential for Embryonic Development
(A and B) Morphology of Rexo2+/+ (A) and Rexo2/ (B) embryos at embryonic day 8.5. Scale bar, 500 mm.
(C) Western blot of REXO2 levels in hearts from control (L/L) and tissue-specific Rexo2 knockout (L/L, cre) mice. VDAC is used as a loading control.
(D) mtDNA copy number in control and Rexo2 knockout mice measured by qPCR using three TaqMan probe sets to different regions of the mitochondrial
genome.mtDNA levels are normalized to the level ofActin and representmean values from 3 independent experiments with total n = 15mice for each group; error
bars represent SEM.
(E) Mitochondrial mRNA steady-state levels in control and Rexo2 knockout mice analyzed by northern blotting. Data are normalized to the level of 18S rRNA and
presented as mean values from 3 independent experiments with total n = 10 mice for each group; error bars represent SEM.
(F) mt-tRNA steady-state levels in control andRexo2 knockoutmice analyzed by northern blotting. Data are normalized to the level of 5.8S rRNA and presented as
mean values from 3 independent experiments, with n = 15 mice for each group.
(G) Level of the pApA RNA dinucleotide in heart tissue from control andRexo2 knockout micemeasured using LC-MS/MS. Data represent mean values from n = 3
mice for each group; error bars represent SEM, **p < 0.01.
(H) Level of the pApA RNA dinucleotide in isolated mitochondria from heart tissue of control and Rexo2 knockout mice measured using LC-MS/MS.
Data represent mean values from n = 3 mice for each group; error bars represent 1 SEM. n.p. indicates no peak.
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scription products was used to determine the exact site at which
this nanoRNA anneals to the promoter during transcription initia-
tion. This revealed amixture of different RNA 50 ends (Figure S7A),
indicating that only the 30 end of this nanoRNA is required to
anneal in order to prime transcription, although transcript length
may also be influenced by reiterative initiation at the TSS. We
therefore also tested the ability of poly(A) nanoRNAs of different
lengths to prime transcription from the LSP or HSP. All poly(A)
sequences tested were capable of efficiently stimulating pro-
moter-dependent transcription (Figures 6E, 6F, S7B, and S7C).The addition of the mitochondrial transcription elongation factor
TEFM into nanoRNA-primed transcription reactions reduced the
rate of pre-termination by the transcription complex, as expected
(Jiang et al., 2019;Minczuk et al., 2011; Posse et al., 2015), but did
not alter the rate of transcription initiation (Figures S7D and S7E,
compare lanes 3–8 with lanes 9–14), indicating that TEFM does
not contribute to transcription primed by nanoRNAs.
Loss of REXO2 Causes an mtRNA Processing Defect
We carried out RNA sequencing (RNA-seq) of RNA from
Rexo2 knockout mice and wild-type controls followed byMolecular Cell 76, 1–13, December 5, 2019 7
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Figure 5. Loss of REXO2 Causes nanoRNA-
Primed Non-canonical Mitochondrial Tran-
scription Initiation
(A) A complete map of changes in 5ʹ-end abun-
dance (log2 fold change [knock out (KO)mean/
control (Ctrl)mean]) from three control (L/L) and
three Rexo2 knockout (L/L, cre) mice on heavy
(top) and light (bottom) strands. Mean increases
are shown in red and mean decreases in blue. A
schematic of the mitochondrial genome is dis-
played in the center; rRNAs are displayed in green,
mRNAs in blue, tRNAs in gray, and the non-coding
region (NCR) in black.
(B) Frequency of all possible dinucleotide com-
binations found at the 5ʹ ends of captured
sequence tags in three control and Rexo2
knockout mice.
(C) In vitro transcription reactions using super-
coiled pBluescript II SK (+) DNA as a template.
Reactions contain 20 mM ATP, CTP, and GTP;
1 mM UTP; 0.2 mCi 32P a-UTP; and 20 mM of the
indicated RNA or DNA oligonucleotide.
(D) In vitro transcription reactions as in (C) but
containing BamHI-linearized pBluescript II SK (+)
DNA as a template. Reactions using a super-
coiled template (lanes 12 and 13) are included as
a positive control.
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lecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.09.010differential expression analysis, which found no significant
changes in the overall levels of mitochondrial transcripts and
no large changes in nuclear gene expression (Table S2). We
used the RNA-seq data to investigate if the increased pres-
ence of dinucleotides as a consequence of REXO2 loss can
interfere with RNA processing and thereby cause an accumu-
lation of mtRNA precursors. RNA-seq captures longer RNAs,
such as mRNAs and rRNAs, but excludes mature tRNAs,
providing a way to investigate the accumulation of tRNA-con-8 Molecular Cell 76, 1–13, December 5, 2019taining precursor transcripts in mito-
chondria since they are produced from
the same polycistronic transcript (Rack-
ham et al., 2016; Siira et al., 2018). We
identified increases in the levels of pre-
cursor transcripts across the tRNA junc-
tions that span each mRNA (Figure 7A)
and rRNA (Figure 7B). To show that
the accumulated transcripts were not
only a consequence of increased tran-
scription in the absence of REXO2,
we also investigated the PARE datasets
for changes in canonical cleavage
sites across the entire mitochondrial
transcriptome. In the REXO2 knockout
mice, we identified decreases in the
levels of 5ʹ tRNA canonical sites,
whereas the levels of 3ʹ tRNA cleavage
sites or non-canonical sites were either
increased or not affected in the absence
of REXO2 (Figure 7C). This suggests
that an increased abundance of dinu-cleotides interferes with the processing of 5ʹ ends of
mt-RNAs.
DISCUSSION
We have established REXO2 as a specialized dinucleotide-de-
grading enzyme in mammalian mitochondria. REXO2 acts as
the final stage in mtRNA degradation, as the mononucleotides
released by REXO2 can be recycled for further rounds of
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Figure 7. Loss of REXO2 Causes an RNA Processing Defect
(A and B) A complete map of mtRNA abundance and mean (log2 fold change [KOmean/Ctrlmean]) determined by RNA-seq coverage from control (n = 3) and
Rexo2 knockout (n = 3) mice on the heavy (upper) and light (lower) strand with the mtDNA genome positioned in the centre. Increases (red) and decreases (blue)
are depicted for the coding regions (A) and rRNA regions (B).
(C) Changes in the levels of canonical mtRNA junctions were determined from the PARE datasets.
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lecular Cell (2019), https://doi.org/10.1016/j.molcel.2019.09.010transcription. The best-characterized ribonuclease involved in
mtRNA degradation, PNPase, is unable to degrade substrates
of less than 4 nt in length (Lin et al., 2012) and therefore acts up-
stream of REXO2 in mtRNA degradation. However, it remains
unclear whether these products of PNPase are further pro-
cessed by other RNases or whether other enzymes also
generate substrates for REXO2. The mitochondrial nucleaseFigure 6. Loss of REXO2 Causes Transcription Dysregulation at Mitoc
(A and B) Genome browser view (log scaled) of the abundance from three contro
relative changes (log2 fold change[KOmean/WTmean]) in RNA-seq and PARE libra
direction of transcription from the LSP and HSP is indicated, and the cleavage s
(C) Schematic (top) shows the experimental setup of in vitro transcription rea
LSP promoter sequence. Reactions (bottom) contain linearized or supercoiled LS
32P a-UTP; and 20 mM of the indicated RNA oligonucleotide (red). Oligonucleot
scription start site as indicated. ‘‘RO’’ indicates the runoff transcription product,
(D) In vitro transcription reactions as in (C) but containing linearized or superco
oligonucleotide (red) that is not complementary to the HSP sequence is shown in
(E) In vitro transcription reactions as in (C) but using poly(A) RNA (red) or DNA (b
(F) In vitro transcription reactions as in (D) but using poly(A) RNA (red) or DNA (bl
10 Molecular Cell 76, 1–13, December 5, 2019ExoG releases dinucleotides as reaction products and is active
upon RNA (Szymanski et al., 2017; Wu et al., 2019) and so could
potentially fulfill this role. Interestingly, a very recent study of
E. coli Orn has similarly revealed a stark preference for diribonu-
cleotide substrates (Kim et al., 2019), suggesting that oligoribo-
nucleases have a more specialized and evolutionarily conserved
role than previously understood. A second potential source ofhondrial Promoters
l (L/L) and three Rexo2 knockout (L/L, cre) mice (mean normalized count) and
ries showing the abundance of 5ʹ endsmapped to the HSP (A) and LSP (B). The
ite between tRNA-Phe (TF) and 12S rRNA is indicated by an upward arrow.
ctions and complementarity between RNA oligonucleotides and the human
P-containing plasmid template; 20 mM ATP, CTP, and GTP; 1 mMUTP; 0.2 mCi
ide sequences are designed to anneal to the promoter sequence at the tran-
and ‘‘PT’’ indicates transcription products prematurely terminated at CSB2.
iled human HSP-containing plasmid as a template. A base in the AAAA RNA
yellow in the schematic.
lack) oligonucleotides.
ack) oligonucleotides.
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by POLRMT. Similarly to RNA polymerases in other systems,
POLRMT engages in frequent rounds of abortive transcription
initiation, releasing very short RNA products (Carpousis and
Gralla, 1980; Gaspari et al., 2004; Luse and Jacob, 1987). As
these RNAs are capable of annealing to the TSS, their rapid
degradation is presumably required to prevent their use as
primers.
The capacity of REXO2 to also efficiently degrade DNA dinu-
cleotides (Figure 1C) suggests that REXO2 may also be involved
in the terminal stage of mtDNA breakdown. Two recent studies
have implicated the 30–50 exonuclease (proofreading) activity of
the mitochondrial DNA polymerase POLg and the exonuclease
MGME1 in mtDNA degradation (Nissanka et al., 2018; Peeva
et al., 2018). POLg releases mononucleotides as reaction
products (Kunkel and Soni, 1988), but MGME1 cleaves single-
stranded DNA in a distributive manner to release short oligonu-
cleotides (Kornblum et al., 2013; Szczesny et al., 2013), which
may represent good substrates for REXO2; thus, the role of
REXO2 in mtDNA metabolism warrants further investigation.
The RNA substrates of REXO2 were found to be potent
stimulators of mitochondrial transcription, both from canonical
promoters and non-canonical sites. In bacteria, it has been sug-
gested that the priming of transcription by nanoRNAs is a phys-
iological mechanism to regulate the activity of certain promoters,
as the rate of nanoRNA-primed transcription varies according to
the growth stage of the cells (Druzhinin et al., 2015; Vvedenskaya
et al., 2012). The observation that nanoRNAs alter the rate of
transcription initiation from both mitochondrial promoters
(Figure 6) suggests that such a system is formally possible in
mammalian mitochondria. However, the fact that the same
nanoRNAs also prime transcription at non-canonical sites
(Figure 5) makes such a system appear unlikely unless additional
mechanisms exist to maintain promoter specificity in vivo. The
stimulation of in vitro transcription initiation by nanoRNAs (Fig-
ure 6) suggests that the formation of the first phosphodiester
bond by POLRMT represents a rate-limiting step for transcrip-
tion initiation. This observation is in agreement with previous
studies showing that the yeast mtRNA polymerase requires
high ATP concentrations for the formation of the first phospho-
diester bond, but not for elongation (Amiott and Jaehning,
2006a, 2006b). This ATP sensing mechanism could potentially
couple transcription levels to respiration. For this model to func-
tion, AA dinucleotides, in which the first phosphodiester bond
has already been formed, must be eliminated so that they do
not serve as primers for transcription. REXO2 may serve this
purpose.
The use of ATP as an initiating nucleotide leads to primary
transcripts carrying a triphosphate at the 50 end. In E. coli, this
triphosphate acts to stabilize transcripts, while decapping of
the RNA leads to the degradation of the resulting monophos-
phorylated transcript by RNase E (Deana et al., 2008). The pos-
sibility of a similar mechanism operating in mammalian mito-
chondria is precluded by the fact that the processing of
polycistronic mtRNA precursors leads to the mature transcripts
bearing a 50 monophosphate (Ojala et al., 1981) and means
that other mechanisms must be required to mark mitochondrial
transcripts for degradation. Selective degradation of antisensemtRNAs has recently been suggested to be mediated by
GRSF1 in conjunction with the degradosome (Pietras et al.,
2018), but there is currently no known mechanism to distinguish
between full-length and truncated sense-strand transcripts. This
would presumably make it difficult to distinguish between
mature transcripts and those initiated from non-canonical sites
in mitochondria and helps to explain why transient depletion of
REXO2 causes severe effects upon mitochondrial gene expres-
sion (Bruni et al., 2013).
The importance of a dinucleotidase activity is highlighted by
the fact that REXO2 is essential for embryonic development (Fig-
ure 4). The finding that a heart-specific knockout of REXO2 was
viable was therefore surprising but presumably reflects a greater
requirement for this activity in proliferative tissues during devel-
opment. The knockout of REXO2 results in embryonic lethality at
around E8.5, similar to other genes involved in mtDNA mainte-
nance and expression (Cerritelli et al., 2003; Larsson et al.,
1998; Milenkovic et al., 2013). The role of the cytosolic form of
REXO2 therefore appears less critical but would represent an
interesting topic for future study.
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Oligonucleotides
2-5-mer RNA and DNA oligos, see Table S3 This paper N/A
Primer for qPCR, see Table S3 This paper N/A
Primers for Northern blot probes, see Table S3 This paper N/A
pApA, standard for mass spectrometry Biolog Cat#P033
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Recombinant DNA
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featureCounts Walter and Eliza Hall Institute http://bioinf.wehi.edu.au/featureCounts/
DESeq 2 Bioconductor https://bioconductor.org/packages/release/bioc/
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CLC Genomics Workbench QIAGEN https://www.qiagenbioinformatics.com/products/
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R The R Project for Statistical
Computing
https://www.r-project.org/
MultiGauge V3.0 Fujifilm N/A
GraphPad Prism GraphPad Software https://www.graphpad.com/scientific-software/prism/
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Mice
All mice in this study had an inbred C57BL/6N background. Animal studies were approved by the animal welfare ethics committee
and performed in compliance with National and European law.
METHOD DETAILS
Cloning and Purification of REXO2
Codon-optimized (Genscript) DNA constructs corresponding to amino acids 39-216 of human REXO2 was cloned in a pETM-11 vec-
tor (EMBL). REXO2 was expressed in Rosetta 2 cells (EMD chemicals) by autoinduction in Magic media (Invitrogen) at 25C for 16
hours. After lysis, the proteins were purified over a His-Select Ni2+ (Sigma-Aldrich) resin and dialyzed against H-0.2 (25 mM Tris-
HCl [pH 7.8], 0.5 mM EDTA, 10% glycerol, 1 mMDTT, 0.2 M NaCl) after the addition of TEV protease at a 1:10 protease:protein ratio.
Further purification was conducted over a HiLoad 16/60 Superdex 200 pg gel filtration column (GE Healthcare) in buffer H-0.2 lacking
glycerol and concentrated using Vivaspin concentrators (10,000 Da MWCO, Sartorius). Dimerization mutants were dialyzed against
H-0.1 after the Ni2+ purification step and further purified over a Hitrap-Q (1 ml) column equilibrated in H-0.1. After washing with H-0.1
the proteins were elutedwith a 30mL linear gradient betweenH-0.1 andH-1.0. The dimerization state was determined on a Superdex
75 increase (GE Healthcare) column equilibrated in H-0.5 lacking glycerol.
Nuclease Assays
REXO2 nuclease assays were performed according to the method of Nguyen et al. (2000). RNA and DNA substrates were 50 end
labeled using T4 polynucleotide kinase (NEB) according to the manufacturer’s instructions and purified using MicroSpin G-25 col-
umns (GE Healthcare). Nuclease reactions (10 ml) contained 10 fmol of labeled substrate, 50 mM HEPES-KOH pH 7.4, 50 mM
KCl, 10 mMMnCl2, 0.01% Triton X-100, 10% glycerol, 0.1 mM DTT and the indicated amount of REXO2 protein prepared in dilution
buffer (200 mM NaCl, 100 mg/ml BSA, 0.5 mM EDTA, 20 mM Tris-Cl pH 8, 1 mM DTT, 10% glycerol). Reactions were incubated at
37C for 30 min then stopped by the addition of 10 ml loading buffer (98% formamide, 10 mM EDTA, 0.025% xylene cyanol and
0.025% bromophenol blue) and separated by 18% denaturing PAGE. Gels were exposed to storage phosphor screens and scanned
using a Fujifilm FLA-7000 for quantification, or exposed to X-ray film.
Crystallization and Structure Determination
Crystals of REXO2 were grown at 23C by the hanging drop vapor diffusion method by mixing 1 mL protein (20 mg/ml) with an equal
volume of reservoir solution (100 mM HEPES pH 7.0, 200 mM sodium malonate, and 20% polyethylene glycol 3350). For soaking
experiments, REXO2 D199A mutant crystals were incubated in a fresh drop containing 100 mM MES pH 5.5, 200 mM sodium
malonate, 20% polyethylene glycol 3350, 20 mMMgCl2, 1 mM ZnCl2, 12% glycerol and 1 mM oligonucleotide for 30-60 min. Diffrac-
tion data were collected at beamlines 14-1 (Bessy, Berlin, Germany) and ID29 (ESRF, Grenoble, France). The data (Table 1) were
processed with XDS (Kabsch, 1993) and the structure was solved by molecular replacement with Phaser (McCoy et al., 2005), using
ORN from Escherichia coli (PDB: 1YTA) as searchmodel. Themolecular replacement solution was used as a starting model for build-
ing by Autobuild (Adams et al., 2010) that was further improved bymanual building in COOT (Emsley and Cowtan, 2004) interspersed
with refinement in Buster (Smart et al., 2012), which rendered a final model (Table 1) that had no Ramachandran outliers as assessed
by MolProbity (Lovell et al., 2003). A dataset collected near the peak of anomalous scattering by zinc (1.28 A˚) was collected for the
DNA bound REXO2. Both dinucleotide bound structures were solved bymolecular replacement using the apo structure as the search
model. Figures were prepared with Pymol (Schro¨dinger).
Generation of Rexo2 Conditional Knockout Mice
The Rexo2 conditional knockout mice were generated by Taconic Artemis. Exons 3-5 of the Rexo2 locus were flanked by loxP sites,
and two positive selection markers including a neomycin resistance cassette (NeoR) flanked by Frt sites and a puromycin resistance
cassette (PuroR) flanked by F3 sites were introduced in intron 2 and intron 5, respectively. The NeoR and PuroRwere removed by the
mating of Rexo2+/loxP-Neo-Puro mice with transgenic mice ubiquitously expressing Flp-recombinase. After the Flp recombination, the
resulting Rexo2+/loxP mice were subsequently crossed with transgenic mice ubiquitously expressing cre-recombinase under the
control of (1) the b -actin promoter (+/b -actin) to generate Rexo2 heterozygous knockout mice (Rexo2+/) or (2) the muscle
creatinine kinase promoter (+/Ckmm-cre) to generate heart and skeletal muscle Rexo2 conditional knockout mice (Rexo2loxP/loxP,
+/Ckmm-cre; L/L, cre).
Crude Mitochondrial Isolation
Mitochondria from mouse heart were isolated by differential centrifugation using isolation buffer (320 mM sucrose, 10 mM Tris-HCl,
pH 7.4 and 1 mM EDTA), supplemented with protease inhibitor (Roche). Hearts were homogenized using a Potter-Elvehjem homog-
enizer on ice (15 strokes, 500 rpm). Nuclei and cell debris were pelleted at 1,000 g for 10 minutes at 4C. The supernatant was
centrifuged at 10,000 g for 10 min at 4C. The differential centrifugation was repeated twice to obtain the crude mitochondria.e3 Molecular Cell 76, 1–13.e1–e6, December 5, 2019
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Crude mitochondria or total protein (10-30 mg) were resuspended in 1 x NuPAGE LDS Sample Buffer. Mitochondrial proteins were
separated by SDS-PAGE (4%–12% Bis-Tris Protein Gels; Invitrogen) and transferred onto Polyvinylidene difluoride (PVDF) mem-
branes (Merck Millipore). Immunoblotting was performed using standard procedures and developed using ECL Reagent.
RNA Extraction, Quantitative PCR and Northern Blot Analysis
RNA was extracted from heart using Trizol reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions, then
treated with TURBO DNA-free DNase (Thermo Fisher Scientific). For qPCR expression analysis, cDNA was reversed transcribed
from1 mg total RNA usingHigh-Capacity cDNAReverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCRwas performed
in a QuantStudio 6 Flex Real-Time PCR System (Life Technologies), using (1) TaqMan Universal Master Mix II, with UNG to quantify
mitochondrial transcripts (mt-rRNAs and mt-mRNAs) and Actin, and (2) Platinum SYBR Green qPCR supermix-UDG (Invitrogen) to
quantify the levels of Rexo2 and Actin. Primer sequences are shown in Table S3.
For northern blotting, 5 mg of total RNA was separated in either 1% MOPS-formaldehyde agarose gels to detect mt-mRNAs and
mt-rRNAs or neutral 10% polyacrylamide gels to detect mt-tRNAs. Separated RNAs were then transferred to Hybond-N+ mem-
branes (GE Healthcare) and hybridized with (1) randomly [32P] dCTP-labeled dsDNA probes, following the Prime-It II Random Primer
Labeling Kit (Agilent), to detect mt-mRNAs (except Nd6), mt-rRNAs, 18S rRNA and 5.8S rRNA; (2) strand-specific oligonucleotide
probes labeled with [32P] dATP, using T4 Polynucleotide Kinase (New England Biolabs), to detect mt-tRNAs. Radioactive signals
were captured in a phosphorImager screen and was quantified using a Typhoon 7000 FLA and the ImageQuant TL 8.1 software
(GE Healthcare).
DNA Isolation, Quantification of mtDNA
Genomic DNA frommouse heart was isolated with the DNeasy Blood and Tissue Kit (QIAGEN) following manufacturer’s instructions,
followed by treatment with RNase A. Mitochondrial DNA copy number was measured by quantitative PCR using 5 ng of DNA in a
QuantStudio 6 Flex Real-Time PCR System using TaqMan Universal Master Mix II. The TaqMan assays were used for the detection
of mtDNA were Nd1, Cox1 and Cyb. 18S was used to normalize for nuclear input.
Measurement of Dinucleotide Concentrations
Quantification of the linear dinucleotide pApA was performed by HPLC-coupled tandemmass spectrometry (LC-MS/MS), based on
our standard method (Burhenne and Kaever, 2013). Crude mitochondria were suspended in 1200 ml ice-cold extraction solution
(acetonitrile/methanol/water, 2:2:1 v/v/v, HPLC grade), or 75mg heart tissuewasmixedwith 600 ml ice-cold extraction solution. Heart
tissue was homogenized using a FastPrep FP120 (Thermo Savant) at 4.5 m/s for 40 s. Extracted suspensions were transferred to a
new tube, and the tube used for homogenization waswashedwith 23 300 ml extraction solution and combinedwith the homogenate.
Samples were extracted by incubation at 95C for 10 minutes, then stored at 20C overnight to enforce protein precipitation.
Precipitated protein was pelleted by centrifugation at 20,800 g for 10 minutes at 4C, and the supernatant dried using a SpeedVac.
The dried extracts were dissolved in 150 ml H2O and HPLC separation was conducted by a Shimadzu LC-10 series chromatograph
equipped with an EC 50/3 Nucleodur C18 Pyramid column (Macherey & Nagel), additionally coupled with a C18 security guard
(Phenomenex) and a 0.5 mm column saver (Supelco). For separation of pApA, gradient elution at 30C was used (solvent A,
10 mM ammonium acetate/0.1% acetic acid; solvent B, methanol; 0 to 4 min, 100% A; 4 to 7.3 min, 90% A; 7.3 to 8.3 min, 90%
A; 8.3 to 11 min, 70% A; 11 to 11.1 min, 100% A, 11.1 to 13 min, 100%A). Retention time of pApA was 6.6 min. MS/MS analysis
was carried out by an API4000 mass spectrometer (Sciex) operating in positive electrospray and multiple reaction monitoring
mode. As main mass transitions [M+H]+ for pApA m/z 676.9 to 136.0 (quantifier) and 676.9 to 119.1 (identifier) were recorded.
Quantification was done in comparison to authentic pApA (Biolog) and tenofovir as internal standard. For quantification of
dinucleotide levels, precipitated cell pellets were dissolved in 800 ml of 0.1 N NaOH and heated to 95C for 15 minutes. Protein
concentrations were determined using a BCA assay.
Measurement of Nucleotide Concentrations
Nucleotides from freshly dissected heart tissues and from isolated mitochondria were extracted by homogenization in 250 ml of ice-
cold 12% TCA-15mMMgCl2 solution followed by two rounds of neutralization steps using Freon-Trioctylamine mix. For determining
the NTP levels, 50 ml of heart tissue samples or 150 ml of mitochondrial samples were analyzed by HPLC as described in Watt et al.
(2016). NTP levels were normalized to the total protein content in each sample, determined using a BCA assay.
RNA Sequencing and Analyses
Total RNA was isolated from three control and three Rexo2 knockout mouse hearts using a miRNeasy Mini Kit (QIAGEN), incor-
porating an on-column RNase-free DNase digestion, according to manufacturer’s instructions. RNA quantity, purity and integ-
rity were verified using a Bioanalyzer. RNA sequencing was performed by the Cologne Genomics Centre (Cologne, Germany) on
the Illumina HiSeq platform, according to the Illumina Tru-Seq protocol, using random hexamer primers for cDNA library gen-
eration and cytoplasmic rRNA depletion using the Ribo-Zero rRNA removal kit. Sequenced reads were aligned to the mouse
genome reference sequence (mm10), masked for NUMTs regions, with bowtie2 v2.3.4.1 (Langmead and Salzberg, 2012),Molecular Cell 76, 1–13.e1–e6, December 5, 2019 e4
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to full-length RNA fragment BED files, before coverage was calculated with BEDtools (Quinlan and Hall, 2010) genomecov
(-d -scale [1e+06/total mapped reads]), normalized to the total number of fragments mapped to the mouse whole genome
(reads per million; RPM), and converted to wig format for visualization. Gene-level counts for the nuclear genome were calcu-
lated with featureCounts (Liao et al., 2014) (-C –p –B –P -s 2) using the GENCODE vM20 annotation and a GENCODE-based
mitochondrial annotation with contiguous mt-Atp8/6 and mt-Nd4l/4 intervals, and an approximate 7S RNA annotation
(chrM:16035-16188). Count tables were collated in R v3.5.2 (R Development Core Team, 2010) and differential expression
between conditions was analyzed with DESeq2 v1.22.2 (Love et al., 2014).
PARE and Analysis
PARE library preparation and sequencing was performed on RNA isolated from heart mitochondria from three control and three
Rexo2 knockout mouse hearts using a miRNeasy Mini Kit, as previously described (Mercer et al., 2011; Rackham and Filipovska,
2014) and sequencing was performed by Vertis Biotechnologie (Freising, Germany). The 5-bp adaptor sequence was trimmed
and paired-end reads were merged with CLC Genomics Workbench (QIAGEN) if the read overlap exceeded 95% identity. Merged
reads were aligned to the mouse genome (mm10) with Bowtie2, using the–very-sensitive preset parameters with a shortened seed
length of 10 nt (Langmead and Salzberg, 2012), and strand-specific read coverage at the 5ʹ terminal position of aligned reads was
calculated with BEDtools (Quinlan and Hall, 2010) genomecov (-d -scale [1e+06/total mapped reads]), normalized to the total number
of fragments mapped to the mouse whole genome (reads per million; RPM), and converted to wig format for visualization. Relative
changes were calculated as log2 fold changes of the mean normalized 5
0 end coverage for three control (L/L) or knockout (L/L, cre)
mice, plus a pseudocount of one. The genomic positions of the 50 terminal nucleotides of all mapped reads were extracted using
samtools, bedtools and awk. The corresponding strand-specific genomic sequences were extracted from the reference sequence
and counted using bedtools and bash functions, and normalized to library size.
Purification of Proteins for in vitro Transcription
His-tagged human POLRMT, TFAMand TFB2Mwere expressed individually inSpodoptera frugiperda (Sf9) suspension cells infected
with Autographa californica nuclear polyhedrosis virus stocks that were prepared using the BacPAK system (Clontech) according to
manufacturer’s instructions. Cells were collected 60-72 hours after infection and freeze-thawed in liquid nitrogen into a lysis buffer
consisting of 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM b-mercaptoethanol and 1 3 proteinase inhibitors (1 mM PMSF, 2 mM
pepstatin A, 0.6 mM leupeptin and 2 mM benzamidine in 100% ethanol). Proteins were purified by nickel and heparin affinity chro-
matography according to the method of Falkenberg et al. (2002). His-tagged human TEFM (residues 36-360) was expressed in KRX
cells (Promega) and purified using sequential nickel affinity, heparin and gel filtration columns according to the method of Posse
et al. (2015).
In vitro Transcription Reactions
Templates lacking a promoter sequence for in vitro transcription reactions consisted of pBluescript II SK(+), in either super-
coiled form or linearized using BamHI and purified using a gel extraction kit (QIAGEN). Promoter-containing templates consisted
of pUC18 containing the human mtDNA sequence region m. 1-477 (for LSP templates) or m. 499-742 (for HSP templates), in-
serted between BamHI and HindIII restriction sites. Where indicated, templates were linearized using BamHI (for LSP templates)
or HindIII (for HSP templates) and purified using a PCR purification kit (QIAGEN). Standard in vitro transcription reactions (25 ml)
consisted of 90 fmol DNA template, 500 fmol POLRMT, 500 fmol TFB2M, 5 pmol TFAM, 10 mM Tris-HCl (pH 8.0), 10 mM MgCl2,
64 mM NaCl, 100 mg/ml BSA, 1 mM DTT, 4 U murine RNase inhibitor, 10 mM UTP, 0.02 mM [a-32P] UTP (3000 Ci/mmol), and
ATP, CTP and GTP as indicated in figure legends (either 20 mM each or 100 mM each). 1 pmol TEFM was also included where
indicated. Reactions were allowed to proceed at 32C for 30 minutes, before being stopped by the addition of 200 ml stop buffer
(10 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 150 mg/ml proteinase K and 0.1 mg/ml glycogen). Reactions were
incubated for a further 45 minutes at 42C before being ethanol precipitated and resuspended in 10 ml loading buffer (98% form-
amide, 10 mM EDTA, 0.025% xylene cyanol and 0.025% bromophenol blue). Reactions were separated by 4% denaturing TBE-
PAGE and imaged by autoradiography.
Primer Extension
In vitro transcription reactions were carried out as above, except that radiolabelled UTP was omitted and all NTPs were present
at a final concentration of 100 mM. Following precipitation, transcription products were resuspended in 10 ml H2O. This product
(5 ml) was incubated with 1 pmol of end-labeled hLSP_PEx primer (labeled using T4 PNK according to manufacturer’s instruc-
tions) at 65C for 5 minutes then chilled on ice. Reverse transcription primer extension was carried out in first-strand buffer
(50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2) with the addition of 10 mM DTT, 1 U RNase inhibitor, 0.5 mM each
dNTP and 50 U SuperScript II (Thermo Scientific) at 42C for 50 minutes, followed by inactivation at 70C for 15 minutes. An
equal volume of loading buffer was added and products were separated by 10% urea-PAGE on sequencing gels, and imaged
by autoradiography.e5 Molecular Cell 76, 1–13.e1–e6, December 5, 2019
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Nuclease assays were quantified using MultiGauge V3.0 (Fujifilm) using images generated from a Fujifilm FLA-7000. Experiments
using mouse samples were performed at least three times and results are representative of n > 5 independent biological replicates,
unless indicated otherwise. All values are expressed as means ± SEM. Statistical significance between two groups was assessed by
two-tailed unpaired Student’s t test. Differences were considered statistically significant at a value of p < 0.05.
DATA AND CODE AVAILABILITY
Crystallography datasets are available at the RCSB Protein Data Bank with accession numbers PDB: 6RCI (REXO2), PDB: 6RCL
(REXO2-pApA) and PDB: 6RCN (REXO2-dAdA).
The Gene Expression Omnibus (GEO) accession number for the data reported in this paper is GEO: GSE129707.
Original imaging data have been deposited in Mendeley Data and are available at https://doi.org/10.17632/ss68bdtccy.1Molecular Cell 76, 1–13.e1–e6, December 5, 2019 e6
